论文部分内容阅读
目的评价美罗华(Rituximah)联合CHOP(R-CHOP)方案治疗CD20阳性B细胞性非霍奇金淋巴瘤(NHL)的临床疗效及不良反应。方法将60例初治B细胞淋巴瘤患者分为R-CHOP组和CHOP组各30例。R-CHOP组采用R-CHOP方案化疗;CHOP组采用CHOP方案化疗。6个疗程后比较两组的临床疗效及不良反应。结果 R-CHOP组完全缓解率达80%,总有效率90%;CHOP组完全缓解率为60%,总有效率为73.3%,两组疗效差异有统计学意义(P<0.01)。两组不良反应差异无统计学意义(P>0.05)。结论美罗华联合CHOP方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。
Objective To evaluate the clinical efficacy and adverse reactions of Rituximah in combination with CHOP (R-CHOP) regimen in the treatment of CD20 positive B-cell non-Hodgkin’s lymphoma (NHL). Methods Sixty patients with newly diagnosed B-cell lymphoma were divided into R-CHOP group and CHOP group, 30 cases each. R-CHOP group with R-CHOP chemotherapy; CHOP group with CHOP chemotherapy. The clinical efficacy and adverse reactions of the two groups were compared after 6 courses of treatment. Results The complete remission rate was 80% and the total effective rate was 90% in the R-CHOP group. The complete remission rate was 60% in the CHOP group and the total effective rate was 73.3%. The difference between the two groups was statistically significant (P <0.01). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion The combination of rituximab and CHOP regimen in the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma has obvious curative effect. Adverse reactions are similar to chemotherapy alone and may be the first choice of the disease.